Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarction

Heart

Volumn 98, Issue 1, 2012, Pages 31-36

  Nilsson, Lennart ^a,b   Hallén, Jonas ^c,d   Atar, Dan ^c,d   Jonasson, Lena ^a,b   Swahn, Eva ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; MYELOPEROXIDASE; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TROPONIN I;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR MAGNETIC RESONANCE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGED; ANGIOPLASTY, BALLOON, CORONARY; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYTIC AGENTS; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PEPTIDE FRAGMENTS; PEROXIDASE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84155164866     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-300079     Document Type: Article

References (35)

1. Thatcher JL, Gilseth TA, Adlis S. Improved efficiency in acute myocardial infarction care through commitment to emergency department initiated primary PCI. J Invasive Cardiol 2003;15:693-8. (Pubitemid 37549286)
2. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20. (Pubitemid 36050955)
3. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357:1121-35.
4. Piper HM, Meuter K, Schäfer C. Cellular mechanisms of ischemia-reperfusion injury. Ann Thorac Surg 2003;75:S644-8. (Pubitemid 36184543)
5. Das UN. Free radicals, cytokines and nitric oxide in cardiac failure and myocardial infarction. Mol Cell Biochem 2000;215:145-52. (Pubitemid 32094953)
6. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002;53:31-47. (Pubitemid 34020764)
7. Kakkar AK, Lefer DJ. Leukocyte and endothelial adhesion molecule studies in knockout mice. Curr Opin Pharmacol 2004;4:154-8. (Pubitemid 38444050)
8. Oyama J, Blais C Jr, Liu X, et al. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 2004;109:784-9. (Pubitemid 38222900)
9. Atar D, Huber K, Rupprecht HJ, et al. Rationale and design of the 'F.I.R.E.' study. A multicenter, double-blind, randomized, placebo-controlled study to measure the effect of FX06 (a fibrin-derived peptide Bbeta(15-42)) on ischemia-reperfusion injury in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Cardiology 2007;108:117-23. (Pubitemid 47295570)
10. Atar D, Petzelbauer P, Schwitter J, et al. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol 2009;53:720-9.
11. Bach TL, Barsigian C, Yaen CH, et al. Endothelial cell VE-cadherin functions as a receptor for the beta15-42 sequence of fibrin. J Biol Chem 1998;273:30719-28. (Pubitemid 28545554)
12. Petzelbauer P, Zacharowski PA, Miyazaki Y, et al. The fibrin-derived peptide Bbeta 15-42 protects the myocardium against ischemia-reperfusion injury. Nat Med 2005;11:298-304. (Pubitemid 40460558)
13. Roesner JP, Petzelbauer P, Koch A, et al. The fibrin-derived peptide Bbeta 15-42 is cardioprotective in a pig model of myocardial ischemia-reperfusion injury. Crit Care Med 2007;35:1730-5. (Pubitemid 46985877)
14. Newby AC. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med 2007;17:253-8. (Pubitemid 350087694)
15. Chow AK, Cena J, Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 2007;152:189-205. (Pubitemid 47517601)
16. Cheung PY, Sawicki G, Wozniak M, et al. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000;101:1833-9. (Pubitemid 30213106)
17. Wang W, Schulze CJ, Suarez-Pinzon WL, et al. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002;106:1543-9.
18. Mukherjee R, Mingoia JT, Bruce JA, et al. Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol 2006;291:2216-28.
19. Lalu MM, Pasini E, Schulze CJ, et al. Ischaemia-reperfusion injury actives matrix metalloproteinases in the human heart. Eur Heart J 2005;26:27-35. (Pubitemid 40221120)
20. Baldus S, Heitzer T, Eiserich JP, et al. Myeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusion. Free Radic Biol Med 2004;37:902-11. (Pubitemid 39078559)
21. Blankenberg S, Rupprecht HJ, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-85. (Pubitemid 36397324)
22. Squire IB, Evans J, Ng LL, et al. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 2004;10:328-33. (Pubitemid 39092685)
23. Webb CS, Bonnema DD, Ahmed SH, et al. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation 2006;114:1020-7. (Pubitemid 44358878)
24. Wagner DR, Delagardelle C, Ernens I, et al. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail 2006;12:66-72. (Pubitemid 43267754)
25. Kelly D, Cockerill G, Ng LL, et al. Plasma matrix metallo-proteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 2007;28:711-18. (Pubitemid 46439245)
26. Kelly D, Khan SQ, Thompson M, et al. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J 2008;29:2116-24.
27. Dall'Armellina E, Karamitsos TD, Neubauer S, et al. CMR for characterization of the myocardium in acute coronary syndromes. Nat Rev Cardiol 2010;7:624-36.
28. O'Regan DP, Ariff B, Neuwirth C, et al. Assessment of severe reperfusion injury with T2*cardiac MRI in patients with acute myocardial infarction. Heart 2010;96:1885-91.
29. Wu E, Ortiz JT, Tejedor P, et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart 2008;94:730-6. (Pubitemid 351744690)
30. Nilsson L, Jonasson L, Nijm J, et al. Increased plasma concentration of matrix metalloproteinase-7 in patients with coronary artery disease. Clin Chem 2006;52:1522-7. (Pubitemid 44148315)
31. Kandasamy AD, Chow AK, Ali MA, et al. Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res 2010;85:413-23.
32. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32:368-72. (Pubitemid 28396484)
33. Fukuda D, Shimada K, Tanaka A, et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol 2006;97:175-80. (Pubitemid 43139231)
34. Lindsey M, Wedin K, Brown MD, et al. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 2001;103:2181-7. (Pubitemid 32458328)
35. Schulze CJ, Wang W, Suarez-Pinzon WL, et al. Imbalance between tissue inhibitor of metalloproteinase-4 and matrix metalloproteinases during acute myocardial [correction of myoctardial] ischemia-reperfusion injury. Circulation 2003;107:2487-92. (Pubitemid 36605233)